Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma

Abstract

Human telomerase reverse transcriptase, hTERT, is the catalytic component of human telomerase. Expression of hTERT confers telomerase activity, indicating that hTERT is the rate-limiting component of human telomerase. Here we report the detection of anti-hTERT auto-antibodies in the sera derived patients with hepatocellular carcinoma using recombinant, purified hTERT as an antigen in an enzyme linked immunosorbent assay (ELISA). The levels of anti-hTERT antibodies in serum correlated with progression to hepatocellular carcinoma. In contrast, we detected only low levels of anti-hTERT auto-antibodies in the sera derived from 18 normal volunteers. The observation of hTERT auto-antibodies in the sera derived from cancer patients suggests that such auto-antibodies constitute novel and specific tumor marker.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Arai K, Masutomi K, Khurts S, Kaneko S, Kobayashi K, Murakami S . 2002 J. Biol. Chem. 277: 8538–8544

  • Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE . 1998 Science 279: 349–352

  • Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM . 1997 Hepatology 25: 75–80

  • Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA . 2001 Genes Dev. 15: 50–65

  • Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA . 1999 Nature 400: 464–468

  • Hiyama E, Hiyama K . 2002 Oncogene 21: 643–649

  • Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM . 1993a J. Clin. Invest. 92: 2419–2426

  • Imai H, Nakano Y, Kiyosawa K, Tan EM . 1993b Cancer 71: 26–35

  • Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM . 1992 Am. J. Pathol. 140: 859–870

  • Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015

  • Kitamoto M, Ide T . 1999 Cancer 85: 245–248

  • Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M . 1997 Gastroenterology 112: 493–500

  • Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL . 1998 Nat. Genet. 19: 182–186

  • Masutomi K, Kaneko S, Hayashi N, Yamashita T, Shirota Y, Kobayashi K, Murakami S . 2000 J. Biol. Chem. 275: 22568–22573

  • Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Ide T, Ishikawa F . 1998 Nat. Genet. 18: 65–68

  • Nelson DS . 1977 Pathology 9: 155–160

  • Nouso K, Urabe Y, Higashi T, Nakatsukasa H, Hino N, Ashida K, Kinugasa N, Yoshida K, Uematsu S, Tsuji T . 1996 Cancer 78: 232–236

  • Saeboe-Larssen S, Fossberg E, Gaudernack G . 2002 J. Immunol. Methods 259: 191–203

  • Schattner A, Shani A, Talpaz M, Bentwich Z . 1983 Cancer 52: 2156–2161

  • Shay JW, Wright WE . 1996 Trends Genet. 12: 129–131

  • Tan EM . 1991 Cell 67: 841–842

  • Treon SP, Raje N, Anderson KC . 2000 Semin. Oncol. 27: 598–613

  • Vonderheide RH . 2002 Oncogene 21: 674–679

  • Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM . 2001 Cancer Res. 61: 8366–8370

  • Wasserman J, Glas U, Blomgren H . 1975 Clin. Exp. Immunol. 19: 417–422

  • Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP . 1992 Cancer Res. 52: 4168–4174

Download references

Acknowledgements

We thank Dr T Yamashita for critical comments and Ms K Kuwabara for excellent technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shuichi Kaneko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masutomi, K., Kaneko, S., Yasukawa, M. et al. Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 21, 5946–5950 (2002). https://doi.org/10.1038/sj.onc.1205788

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1205788

Keywords

This article is cited by

Search

Quick links